Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of BOTOX in urinary incontinence due to neurogenic detrusor overactivity
2009-009216-53Phase 3Completed
- Sponsor
- Allergan
- Start
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of botulinum toxin type A in detrusor hyperreflexia (DH) and urinary incontinence (UI) (2 arms), sponsored by Allergan. Primary endpoint: Change from baseline in daily average urinary incontinence episodes. Started Mar 2009; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
detrusor hyperreflexia (DH)urinary incontinence (UI)
Beyond the preview
Go deeper on 2009-009216-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009216-53.